Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Alnylam Pharmace. buy Jefferies Financial Group Inc.

Alnylam Pharmace.
Start price
€273.90
07.07.25 / 50%
Target price
€326.17
07.07.26
Performance (%)
2.34%
End price
€280.30
08.07.26
Summary
This prediction ended on 08.07.26 with a price of €280.30. With a performance of 2.34%, the BUY prediction by Jefferies_Financial_ for Alnylam Pharmace. closed with a slight gain. Jefferies_Financial_ has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Jefferies_Financial_ has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

AI-generated
Performance without dividends (%)
Name 1w 1m 1y
Alnylam Pharmace. 3.192% 3.192% -49.479%
iShares Core DAX® -0.046% 5.960% 7.403%
iShares Nasdaq 100 0.922% 3.693% 28.138%
iShares Nikkei 225® 3.014% 6.638% 48.886%
iShares S&P 500 -0.359% 2.747% 22.530%

Comments by Jefferies_Financial_ for this prediction

In the thread Alnylam Pharmace. diskutieren
Prediction Buy
Perf. (%) 2.34%
Target price 326.170
Change
Ends at 07.07.26

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Jefferies Financial Group Inc. from $328.00 to $384.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

Jefferies Financial Group Inc. 
0
Report Share
07.07.25
In the thread Trading Alnylam Pharmace.
Prediction Buy
Perf. (%) 2.34%
Target price 326.170
Change
Ends at 07.07.26

Die von Jefferies_Financial_ gewählte maximale Laufzeit wurde überschritten

Jefferies Financial Group Inc. 
0
Report Share
08.07.26

Current prediction by Jefferies_Financial_ for Alnylam Pharmace.

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€389.00
30.10.25
€472.69
30.10.26
-50.24%
10:51

Jefferies Financial Group Inc. 
30.10.25 50%